OTC Action: How Analysts Feel About MARINA BIOTECH CMN (MRNA)?

November 23, 2016 - By Marie Mckinney

OTC Action: How Analysts Feel About MARINA BIOTECH CMN (MRNA)?

Upon recent trading, MARINA BIOTECH CMN (OTCMKTS:MRNA) shares caught focus of OTC traders as the price moved $0.004, touching the $0.1 price point. Analyzing past data, MARINA BIOTECH CMN’s shares price was -57.00% in the last 1-year with the 52-Week low of 25.00% and 52-Week high of -80.77%.

Measuring a firm’s market value, also known as market capitalization allows investors and financial analysts assess the size of a firm relative to the market. Market capitalization can be understood as a statistic reflecting the public’s confidence in a firm because the calculation highlights the public’s investing arrangements. Financial institutions can put similarly-sized firms into groups such as mid-cap, small-cap AND large-cap by establishing a firm’s market capitalization.

Market capitalization is a vital financial indicator for two main reasons. Firstly, it helps investors in establishing value comparison between firms with their stocks trading at different levels. Secondly, it helps decide a firm’s size in relation to its peers. A firm’s market cap varies as its shares price changes, so financial editors compute market capitalization for public firms daily. MARINA BIOTECH CMN (MRNA)’s market capitalization is currently $3.29M.

Is Stock Price of MARINA BIOTECH CMN All Set to Breakout to Their Potential? Enroll for Our Newsletter and Peep Into the Inside Scoop!

MARINA BIOTECH CMN’s shares has traded at $-12.92 month over month. The short interest of stock currently stands at 31,000 against short interest of 35,600 last month. Investors have 0.6 days to close the position.

The over-the-counter market is a place where stocks that are not listed on the NASDAQ, NYSE, or AMEX are traded. This term is referred exclusively for marginal or small firms that don’t fulfil the listing guidelines of the regulated stock exchanges. These stocks are sometimes called ‘pink sheet’ stocks, a term coined from the old days when such stocks lists were published on pink paper (now exclusively online). Since these equities are small and frequently financially suspect, OTC stocks are stated to be risky and, thus, are poorly traded. They are rarely traded, which indicate that the prospect of getting a bargain price is better over the stocks listed in an organized market. As a result, some traders are inclined to purchase OTC stocks in anticipation of making fast gains. The possibility of fast money becomes easier following the cheap prices of most of the OTC shares, often under $2.00-$1.00 per share, though it’s made tougher by the fact that detailed information on these equities is scarce and often undependable.

Trading in OTC securities is no different from straight gambling, and it is not suggested for beginners. Over-the-counter market is a decentralized market, with no central physical location. Market participants use communication methods like the telephone, email and proprietary electronic trading systems for trading. The exchange market and over-the-counter (OTC) market are two simple ways to establish a financial market.

Within an OTC marketplace, dealers are termed ‘market makers’ when they quote equity prices where they will sell and buy a currency or security. Trades can be carried out between two members in an OTC market without others being made informed of the transaction price, making OTC markets less reliable than exchanges. They are subject to fewer guidelines, which means increasing problems for investors. OTC markets are used mainly to trade currencies, structured products, derivatives and bonds. OTC markets can be used to trade stocks, such as the OTCQB, OTC Pink and OTCQX marketplaces in the U.S. Dealers that function in the U.S. markets are controlled by the Financial Industry Regulatory Authority, popularly named FINRA.

Receive Breaking News by Registering to our Newsletter! Hit on the Bar Below and Get Information About Stocks that are Geared to Make a Run!

OTC marketplace is a platform where clients and dealers trade with each other just like institutions and corporations do. The price a buyer gets from a seller may vary from the price received for same equity from another seller. The ask-bid margin is often wider for the OTC stocks. OTC markets operate smooth during the normal times, however, their lack of transparency becomes a vicious factor that can result in financial stress, and it was the same case when the 2007-2008 worldwide credit crisis happened. Mortgage-backed equities such as CMOs and CDOs, which were traded solely in the OTC markets, could not be dependably priced as liquidity was poor, and buyers were reluctant to trade in this market. This resulted in an increased count of dealers backing out from market-making activities, increasing the liquidity issue while driving a global credit crunch. The regulatory measures created in as the outcome of the crisis resolved this problem with the setup of clearinghouses for post-trade activities.

Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.

More recent Marina Biotech, Inc. (OTCMKTS:MRNA) news were published by: Streetinsider.com which released: “Marina Biotech (MRNA) to Merge with IthenaPharma” on November 16, 2016. Also Streetinsider.com published the news titled: “Marina Biotech (MRNA) Enters Agreement to Acquire Turing Pharma’s Intranasal …” on May 03, 2016. Streetinsider.com‘s news article titled: “Form 4 Marina Biotech, Inc. For: Nov 15 Filed by: Loren Stefan” with publication date: November 17, 2016 was also an interesting one.

Marina Biotech, Inc. is a biotechnology firm focused on the discovery, development and commercialization of nucleic acid therapies to treat orphan diseases. The company has a market cap of $3.29 million. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis , and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It has a 1.87 P/E ratio. It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>